Latest Headlines
-
Everest Medicines And Kezar Life Sciences Receive IND Approval From China NMPA For PALIZADE Trial In Lupus Nephritis
2/26/2024
Everest Medicines and Kezar Life Sciences, Inc. announced today that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) approved Kezar’s investigational new drug (IND) application for initiation of the Phase 2b PALIZADE trial in China of zetomipzomib in patients with lupus nephritis (LN).
-
HKUMed Develops Groundbreaking Monoclonal Antibody For Treating Cerebral Ischaemia Injury
2/26/2024
A research team from the LKS Faculty of Medicine at the University of Hong Kong (HKUMed) has successfully developed a neutralising monoclonal antibody, 6H2, which targets a harmful protein known to exacerbate damage caused by ischaemic stroke.
-
Drug Discovery At An Atomic Scale
2/26/2024
In the heart of Dr. Sriram Subramaniam’s UBC lab, high-powered microscopes as tall as a city bus are allowing researchers to see the very atoms that make up the proteins in our cells — as well as the diseases that affect them.
-
CellarisBio Launches Out Of Stealth With Robust Cell Target Engagement Platform -- Empowering Drug Discovery For Challenging Targets
2/26/2024
CellarisBio is officially out of stealth mode with the launch of its robust Micro-Tag cell target engagement platform.
-
Nona Biosciences Enters Into Collaboration Agreement With Boostimmune In Antibody-Drug Conjugate Development
2/26/2024
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited committed to cutting-edge technology innovations and providing a total solution from "Idea to IND" ("I to ITM"), announced today that it has entered into a collaboration agreement with Boostimmune, a biotech company dedicated to developing next-generation anti-cancer therapies via modulating immune systems.
-
Ligand Partner Eisai Receives Approval In Japan For Injection Formulation Of Antiepileptic Drug Fycompa
2/22/2024
Ligand Pharmaceuticals Incorporated today announced that its partner Eisai Co., Ltd. obtained marketing authorization approval in January 2024 from the Japanese Ministry of Health, Labour and Welfare for the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel) in Japan as an alternative therapy when oral administration is temporarily not possible.
-
Artiva Biotherapeutics Receives FDA Fast Track Designation For AlloNK In Lupus Nephritis
2/22/2024
Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Artiva’s lead program AlloNK (also known as AB-101) for the treatment of lupus nephritis (LN) in combination with rituximab or obinutuzumab.
-
Immune-Onc Therapeutics Announces Orphan Drug Designation Granted By US FDA For IO-202 (Anti-LILRB4) For The Treatment Of Chronic Myelomonocytic Leukemia (CMML)
2/21/2024
Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage biopharmaceutical company advancing novel therapies in immunology and oncology by targeting myeloid cell inhibitory receptors, today announced that the U.S.
-
Bioxytran’s Oral Antiviral Drug To Enter Dose Optimization Clinical Trial For COVID-19
2/21/2024
BIOXYTRAN, INC. (OTCQB: BIXT), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, announced that the first patients have been treated with ProLectin-M in its dose optimization trial.
-
Vaccinex Announces Multiple New Agreements For Access To ActivMAb® Antigen Virus Technology
2/21/2024
Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease and cancer through the inhibition of SEMA4D, announces that it has entered into eight new antibody discovery agreements integrating use of its proprietary ActivMAb platform to select antibodies against difficult-to-drug transmembrane protein targets.